Segall Bryant & Hamill’s Crinetics Pharmaceuticals CRNX Stock Holding History

Segall Bryant & Hamill’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.86M	Buy	183,199 +3,087	+2%	+$115K	0.08%	283
2026 Q1	$6.54M	Sell	180,112 -9,365	-5%	-$418K	0.09%	277
2025 Q4	$8.82M	Buy	189,477 +8,628	+5%	+$384K	0.12%	247
2025 Q3	$7.53M	Buy	180,849 +4,332	+2%	+$139K	0.1%	269
2025 Q2	$5.08M	Buy	176,517 +30,243	+21%	+$934K	0.07%	312
2025 Q1	$4.91M	Sell	146,274 -4,124	-3%	-$154K	0.08%	314
2024 Q4	$7.69M	Buy	+150,398	New	+$8.41M	0.11%	267

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's CRNX Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Crinetics Pharmaceuticals (CRNX) stake by 1.7% in Q2 2026, buying an estimated $115K and bringing the position to 183,199 shares worth $6.86M. The position accounts for 0.08% of the portfolio, ranked #283.

Segall Bryant & Hamill first reported a position in CRNX in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.82M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Segall Bryant & Hamill held 183,199 shares of Crinetics Pharmaceuticals worth $6.86M as of Q2 2026.
Segall Bryant & Hamill bought 3,087 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $115K.
Crinetics Pharmaceuticals made up 0.08% of Segall Bryant & Hamill's portfolio in Q2 2026, its #283 holding.
Segall Bryant & Hamill first reported a position in Crinetics Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Segall Bryant & Hamill's Crinetics Pharmaceuticals position peaked at $8.82M in Q4 2025.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.